Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer.
Nov 28, 2022
0
8
The results from the major phase III OlympiA trial shows the drug improves survival rates in women who have inherited faults in their BRCA1 or BRCA2 genes.
Mar 17, 2022
0
23
The clinical trial of an old antibiotic for a new purpose is offering hope to thousands of patients with drug-resistant breast cancer whose early remissions have given way to resurgent tumors.
Mar 15, 2022
0
3
A new study led by University of California, Irvine researchers has confirmed a link between altered DNA repair and increased DNA damage associated with spinocerebellar ataxia type 7 (SCA7), a debilitating, sometimes deadly ...
Nov 30, 2021
0
26
A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients ...
Aug 12, 2021
0
247
Drugs that target specific proteins have greatly improved patient outcomes across a broad range of tumor types; however, patients often develop drug resistance and tumor recurrence. There is a great unmet need to identify ...
Jul 29, 2021
0
36
More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance ...
May 10, 2021
0
21
Targeted therapy in early stages of breast cancer can pave the way for a notable higher success rate, shows a study from the University of Bergen, Norway (UiB).
Apr 20, 2021
0
5
Investigators at Wake Forest School of Medicine, part of Wake Forest Baptist Health, have identified a set of new genetic markers that could potentially lead to new personalized treatments for lung cancer.
Apr 14, 2021
0
15
Women with advanced ovarian cancer often face grim statistics, with less than half surviving for five years after their diagnosis. However, a new study suggests that so-called "maintenance therapy" with a targeted cancer ...
Mar 26, 2021
0
2
